Nexalin Technology, Inc. announced on October 22, 2024, plans to commence a new clinical trial in collaboration with the University of California, San Diego (UCSD) and the San Diego VA. This trial will evaluate the effectiveness of Nexalin’s next-generation Gen-3 Halo headset for treating mild Traumatic Brain Injury (mTBI) in veterans.
The Gen-3 Halo headset is designed for use in a virtual clinic model, allowing patients to receive treatment conveniently and privately at home. This approach aims to expand access to care for veterans suffering from mTBI, reducing the need for frequent hospital or clinic visits.
The study, titled “MEG Study of the Transcranial Electrical Stimulation Treatment for Mild Traumatic Brain Injury using the Nexalin Halo Headset that Utilizes the Advanced 15 Milliamp Waveform,” will assess the effects of the Gen-3 Halo headset on brain activity and symptom relief. It builds on previous trials using the Gen-2 device, which showed improvements in MEG signals and pain reduction for mTBI patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.